Indeed, phase 2 and phase 3 clinical trials have demonstrated that once‐weekly basal insulins are similarly or more effective than once‐daily basal insulins in providing glycated haemoglobin (HbA1c) reduction in people with type 1 and type 2 diabetes.12, 13, 14. This evidence concerns the gene INS and type 2 diabetes mellitus.